Targeting Unconventional Pathways in Pursuit of Novel Antifungals

Area of Science:

• Mycology
• Infectious Diseases
• Drug Discovery

Background:

• Invasive fungal infections pose a significant public health threat, particularly to immunocompromised individuals.
• Current antifungal treatments, targeting the fungal cell wall/membrane, face challenges including drug interactions, side effects, and emerging resistance.
• There is a critical need for novel antifungal drug classes with improved efficacy and safety profiles.

Purpose of the Study:

• To review and highlight potential novel antifungal drug targets within essential fungal metabolic pathways.
• To discuss the merits of targeting enzymes in pathways such as enolase, mannitol biosynthesis, and purine nucleotide biosynthesis.
• To explore the potential of small molecules and antibodies for disrupting these vital fungal processes.

Main Methods:

• Literature review of current antifungal treatments and emerging resistance mechanisms.
• Identification and analysis of essential fungal metabolic pathways as potential drug targets.
• Evaluation of specific enzymes (e.g., enolase, mannitol biosynthesis enzymes, purine biosynthesis enzymes) as targets for novel antifungal agents.

Main Results:

• Enolase, and enzymes in mannitol and purine nucleotide biosynthesis pathways are identified as promising antifungal targets.
• Targeting these unconventional pathways offers a strategy to overcome existing drug resistance.
• Further investigation into these pathways is warranted to assess their role in fungal survival and virulence.

Conclusions:

• Disrupting essential fungal metabolic pathways presents a viable strategy for developing novel antifungal drugs.
• Targeting enzymes like enolase and those in biosynthesis pathways can lead to new therapeutic agents against invasive fungal infections.
• Exploiting unconventional targets may overcome limitations of current antifungal therapies and combat resistance.